Search - tctmd.com

Displaying 1 - 20 of 39

Sort: Relevancy | Date

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Correction Issued for Controversial Study Linking COVID-19 Vaccines to ACS Risk

News Daily News

Correction Issued for Controversial Study Linking COVID-19 Vaccines to ACS Risk

December 22, 2021

COVID-19: TCTMD’s Dispatch for December Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for December Week 2

December 13, 2021

Questions Raised About Study Linking mRNA Vaccines to Increased ACS Risk

News Daily News

Questions Raised About Study Linking mRNA Vaccines to Increased ACS Risk

December 03, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

News Daily News

Shock in COVID-19: Types, Triggers, and Treatments Differ, but Outlook Is Grim

November 24, 2021

COVID-19: TCTMD’s Dispatch for November Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 4

November 22, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

News Conference News TCT 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

November 04, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

COVID-19: TCTMD’s Dispatch for October Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 4

October 25, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

COVID-19: TCTMD’s Dispatch for September Week 5

News Daily News

COVID-19: TCTMD’s Dispatch for September Week 5

September 27, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

COVID-19: TCTMD’s Daily Dispatch for September Week 3

News Daily News

COVID-19: TCTMD’s Daily Dispatch for September Week 3

September 13, 2021

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

News Conference News ESC 2021

Both Acute and Chronic Myocardial Injury in COVID-19 Impede 6-Month Survival

September 01, 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

Expired Cardiac Devices May Do Global Good, but Safety Unknown

News Features

Expired Cardiac Devices May Do Global Good, but Safety Unknown

Yael L. Maxwell

August 26, 2021

Marijuana Ups Bleeding, CVA Risks in PCI Patients: Registry Data

News Daily News

Marijuana Ups Bleeding, CVA Risks in PCI Patients: Registry Data

August 16, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.